Flavio Forrer

Summary

Affiliation: University Hospital
Country: Switzerland

Publications

  1. ncbi request reprint Neuroendocrine tumors. Peptide receptor radionuclide therapy
    Flavio Forrer
    Department of Nuclear Medicine, Erasmus Medical Centre Rotterdam, Dr Molewaterplein 40, NL 3015 GD Rotterdam, The Netherlands
    Best Pract Res Clin Endocrinol Metab 21:111-29. 2007
  2. ncbi request reprint A comparison of (111)In-DOTATOC and (111)In-DOTATATE: biodistribution and dosimetry in the same patients with metastatic neuroendocrine tumours
    F Forrer
    Institute of Nuclear Medicine, University Hospital, Petersgraben 4, 4031, Basel, Switzerland
    Eur J Nucl Med Mol Imaging 31:1257-62. 2004
  3. ncbi request reprint Treatment with 177Lu-DOTATOC of patients with relapse of neuroendocrine tumors after treatment with 90Y-DOTATOC
    Flavio Forrer
    Institute of Nuclear Medicine, University Hospital, Basel, Switzerland
    J Nucl Med 46:1310-6. 2005
  4. ncbi request reprint Targeted radionuclide therapy with 90Y-DOTATOC in patients with neuroendocrine tumors
    Flavio Forrer
    Institute of Nuclear Medicine, University Hospital Basel, Switzerland
    Anticancer Res 26:703-7. 2006
  5. pmc Is it possible to predict renal function in small animals using a multi-pinhole SPECT system
    F Forrer
    Eur J Nucl Med Mol Imaging 34:1127-8. 2007
  6. pmc Bone marrow dosimetry in peptide receptor radionuclide therapy with [177Lu-DOTA(0),Tyr(3)]octreotate
    Flavio Forrer
    Department of Nuclear Medicine, Erasmus MC Rotterdam, Dr Molewaterplein 40, NL 3015 GD, Rotterdam, The Netherlands
    Eur J Nucl Med Mol Imaging 36:1138-46. 2009
  7. ncbi request reprint Radiolabeled DOTATOC in patients with advanced paraganglioma and pheochromocytoma
    F Forrer
    Institute of Nuclear Medicine, University Hospital of Basel, Basel, Switzerland
    Q J Nucl Med Mol Imaging 52:334-40. 2008
  8. ncbi request reprint From outside to inside? Dose-dependent renal tubular damage after high-dose peptide receptor radionuclide therapy in rats measured with in vivo (99m)Tc-DMSA-SPECT and molecular imaging
    Flavio Forrer
    Department of Nuclear Medicine, Erasmus MC, Rotterdam, The Netherlands
    Cancer Biother Radiopharm 22:40-9. 2007
  9. ncbi request reprint In vivo radionuclide uptake quantification using a multi-pinhole SPECT system to predict renal function in small animals
    F Forrer
    Department of Nuclear Medicine, Erasmus MC Rotterdam, Dr Molewaterplein 40, 3015 GD, Rotterdam, The Netherlands
    Eur J Nucl Med Mol Imaging 33:1214-7. 2006
  10. doi request reprint Bombesin antagonist-based radioligands for translational nuclear imaging of gastrin-releasing peptide receptor-positive tumors
    Keelara Abiraj
    Division of Radiological Chemistry, University Hospital Basel, Basel, Switzerland
    J Nucl Med 52:1970-8. 2011

Collaborators

Detail Information

Publications26

  1. ncbi request reprint Neuroendocrine tumors. Peptide receptor radionuclide therapy
    Flavio Forrer
    Department of Nuclear Medicine, Erasmus Medical Centre Rotterdam, Dr Molewaterplein 40, NL 3015 GD Rotterdam, The Netherlands
    Best Pract Res Clin Endocrinol Metab 21:111-29. 2007
    ..Furthermore, clinical issues--including indication and timing of therapy--are discussed. Finally, important directions for future research are mentioned to illustrate new strategies for increasing therapy efficacy...
  2. ncbi request reprint A comparison of (111)In-DOTATOC and (111)In-DOTATATE: biodistribution and dosimetry in the same patients with metastatic neuroendocrine tumours
    F Forrer
    Institute of Nuclear Medicine, University Hospital, Petersgraben 4, 4031, Basel, Switzerland
    Eur J Nucl Med Mol Imaging 31:1257-62. 2004
    ....
  3. ncbi request reprint Treatment with 177Lu-DOTATOC of patients with relapse of neuroendocrine tumors after treatment with 90Y-DOTATOC
    Flavio Forrer
    Institute of Nuclear Medicine, University Hospital, Basel, Switzerland
    J Nucl Med 46:1310-6. 2005
    ..Trials with (177)Lu-labeled somatostatin analogs showed less nephrotoxicity. We initiated a prospective study with (177)Lu-DOTATOC in patients with relapsed neuroendocrine tumors after (90)Y-DOTATOC treatment...
  4. ncbi request reprint Targeted radionuclide therapy with 90Y-DOTATOC in patients with neuroendocrine tumors
    Flavio Forrer
    Institute of Nuclear Medicine, University Hospital Basel, Switzerland
    Anticancer Res 26:703-7. 2006
    ..The aim of this study was to assess the efficacy and safety of targeted radionuclide therapy with [90Y-DOTA0, Tyr3]-octreotide (90Y-DOTATOC) in patients with metastatic neuroendocrine tumors...
  5. pmc Is it possible to predict renal function in small animals using a multi-pinhole SPECT system
    F Forrer
    Eur J Nucl Med Mol Imaging 34:1127-8. 2007
  6. pmc Bone marrow dosimetry in peptide receptor radionuclide therapy with [177Lu-DOTA(0),Tyr(3)]octreotate
    Flavio Forrer
    Department of Nuclear Medicine, Erasmus MC Rotterdam, Dr Molewaterplein 40, NL 3015 GD, Rotterdam, The Netherlands
    Eur J Nucl Med Mol Imaging 36:1138-46. 2009
    ..Also, we evaluated the absorbed cross-dose from the source organs (liver, spleen, kidneys and blood), tumours and the so-called "remainder of the body" to the bone marrow...
  7. ncbi request reprint Radiolabeled DOTATOC in patients with advanced paraganglioma and pheochromocytoma
    F Forrer
    Institute of Nuclear Medicine, University Hospital of Basel, Basel, Switzerland
    Q J Nucl Med Mol Imaging 52:334-40. 2008
    ..We evaluated the effectiveness and toxicity of radiolabeled DOTATOC in patients with metastatic paraganglioma and pheochromocytoma...
  8. ncbi request reprint From outside to inside? Dose-dependent renal tubular damage after high-dose peptide receptor radionuclide therapy in rats measured with in vivo (99m)Tc-DMSA-SPECT and molecular imaging
    Flavio Forrer
    Department of Nuclear Medicine, Erasmus MC, Rotterdam, The Netherlands
    Cancer Biother Radiopharm 22:40-9. 2007
    ..We studied renal damage in rats after therapy with different amounts of [(177)Lu-DOTA(0), Tyr(3)]octreotate and investigated (99m)Tc-DMSA (dimercaptosuccinic acid) as a tool to quantify renal damage after PRRT...
  9. ncbi request reprint In vivo radionuclide uptake quantification using a multi-pinhole SPECT system to predict renal function in small animals
    F Forrer
    Department of Nuclear Medicine, Erasmus MC Rotterdam, Dr Molewaterplein 40, 3015 GD, Rotterdam, The Netherlands
    Eur J Nucl Med Mol Imaging 33:1214-7. 2006
    ..In vivo quantification of radiopharmaceuticals has great potential as a tool in developing new drugs. We investigated the accuracy of in vivo quantification with multi-pinhole single-photon emission computed tomography (SPECT) in rats...
  10. doi request reprint Bombesin antagonist-based radioligands for translational nuclear imaging of gastrin-releasing peptide receptor-positive tumors
    Keelara Abiraj
    Division of Radiological Chemistry, University Hospital Basel, Basel, Switzerland
    J Nucl Med 52:1970-8. 2011
    ..The current study aims at developing clinically translatable bombesin antagonist-based radioligands for SPECT and PET of GRPr-positive tumors...
  11. doi request reprint Tetraamine-derived bifunctional chelators for technetium-99m labelling: synthesis, bioconjugation and evaluation as targeted SPECT imaging probes for GRP-receptor-positive tumours
    Keelara Abiraj
    Division of Radiological Chemistry, University Hospital of Basel, 4031 Basel, Switzerland
    Chemistry 16:2115-24. 2010
    ..The promising preclinical results of (99m)Tc-N4-BB-ANT warrant its potential candidature for clinical translation...
  12. ncbi request reprint Diagnostic versus therapeutic doses of [(177)Lu-DOTA-Tyr(3)]-octreotate: uptake and dosimetry in somatostatin receptor-positive tumors and normal organs
    Cristina Müller
    Department of Nuclear Medicine, Erasmus MC Rotterdam, The Netherlands
    Cancer Biother Radiopharm 22:151-9. 2007
    ....
  13. ncbi request reprint Amifostine protects rat kidneys during peptide receptor radionuclide therapy with [177Lu-DOTA0,Tyr3]octreotate
    Edgar J Rolleman
    Department of Nuclear Medicine, Erasmus MC, s Gravendijkwal 230, 3015 CE, Rotterdam, The Netherlands
    Eur J Nucl Med Mol Imaging 34:763-71. 2007
    ..We tested the cytoprotective drug amifostine, which selectively protects healthy tissue during chemo- and radiotherapy, for its renoprotective capacities after PRRT with high-dose [(177)Lu-DOTA(0),Tyr(3)]octreotate...
  14. doi request reprint SPECT study of folate receptor-positive malignant and normal tissues in mice using a novel 99mTc-radiofolate
    Cristina Müller
    Department of Nuclear Medicine, Erasmus Medical Center, Rotterdam, The Netherlands
    J Nucl Med 49:310-7. 2008
    ..In this study SPECT/CT of FR-positive malignant and normal tissues and organs in mice was performed using an improved organometallic (99m)Tc-radiofolate...
  15. doi request reprint Targeted radiotherapy with radiolabeled somatostatin analogs
    Guillaume Nicolas
    Department of Radiology and Nuclear Medicine, University Hospital Basel, 4031 Basel, Switzerland
    Endocrinol Metab Clin North Am 40:187-204, ix-x. 2011
    ..This article reviews the effectiveness and safety of the different protocols and discusses several clinical algorithms used in an attempt to optimize targeted radiopeptide therapy...
  16. ncbi request reprint Radioimmunotherapy with 177Lu-DOTA-rituximab: final results of a phase I/II Study in 31 patients with relapsing follicular, mantle cell, and other indolent B-cell lymphomas
    Flavio Forrer
    Institute of Nuclear Medicine, University Hospital Basel, Basel, Switzerland
    J Nucl Med 54:1045-52. 2013
    ....
  17. doi request reprint Development of a potent DOTA-conjugated bombesin antagonist for targeting GRPr-positive tumours
    Rosalba Mansi
    Division of Radiological Chemistry, University Hospital Basel, Basel, Switzerland
    Eur J Nucl Med Mol Imaging 38:97-107. 2011
    ..We describe a new conjugate, RM2, with the chelator DOTA coupled to D-Phe-Gln-Trp-Ala-Val-Gly-His-Sta-Leu-NH(2) via the cationic spacer 4-amino-1-carboxymethyl-piperidine for labelling with radiometals such as (111)In and (68)Ga...
  18. ncbi request reprint Dose-dependent effects of (anti)folate preinjection on 99mTc-radiofolate uptake in tumors and kidneys
    Cristina Müller
    Department of Nuclear Medicine, Erasmus MC, 3015 CE Rotterdam, The Netherlands
    Nucl Med Biol 34:603-8. 2007
    ..The aim of this study was to investigate the dose dependence of these effects and whether the same results could be achieved with folic acid (FA) or 5-methyl-tetrahydrofolate (5-Me-THF)...
  19. doi request reprint In vitro characterization of (177)Lu-radiolabelled chimeric anti-CD20 monoclonal antibody and a preliminary dosimetry study
    Flavio Forrer
    Institute of Nuclear Medicine, University Hospital Basel, Basel, Switzerland
    Eur J Nucl Med Mol Imaging 36:1443-52. 2009
    ..DOTA-rituximab was prepared as a kit formulation and can be labelled in a short time (<20 min) with either (177)Lu or (90)Y...
  20. pmc Short-term dietary restriction and fasting precondition against ischemia reperfusion injury in mice
    James R Mitchell
    Department of Genetics, Erasmus Medical Center, Cancer Genomics Center, Dr Molewaterplein 50, 3015 GE, Rotterdam, The Netherlands
    Aging Cell 9:40-53. 2010
    ....
  21. ncbi request reprint Effect of amino acid infusion on potassium serum levels in neuroendocrine tumour patients treated with targeted radiopeptide therapy
    Giampiero Giovacchini
    Department of Radiology and Nuclear Medicine, Division of Endocrine Diagnostics and Radionuclide Therapy, University Hospital Basel, 4031, Basel, Switzerland
    Eur J Nucl Med Mol Imaging 38:1675-82. 2011
    ..However, the amino acid solution may have side effects, including hyperkalaemia. The aim of this study was to evaluate the frequency and the magnitude of hyperkalaemia in neuroendocrine tumour (NET) patients undergoing TRT...
  22. doi request reprint Evaluation of a 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid-conjugated bombesin-based radioantagonist for the labeling with single-photon emission computed tomography, positron emission tomography, and therapeutic radionuclides
    Rosalba Mansi
    Division of Radiological Chemistry, University Hospital Basel, Basel, Switzerland
    Clin Cancer Res 15:5240-9. 2009
    ..Here, we compare the new [111In/68Ga]-labeled bombesin-based antagonist RM1 with the agonist [111In]-AMBA for targeting the gastrin-releasing peptide receptor (GRPR)...
  23. doi request reprint Neoadjuvant targeting of glioblastoma multiforme with radiolabeled DOTAGA-substance P--results from a phase I study
    Dominik Cordier
    Department of Neurosurgery, University Hospital Basel, Spitalstrasse 21, 4031, Basel, Switzerland
    J Neurooncol 100:129-36. 2010
    ..The high extent of resection and concomitant irradiation of tumor cells in the infiltration zone may be prognostically relevant...
  24. ncbi request reprint Targeted alpha-radionuclide therapy of functionally critically located gliomas with 213Bi-DOTA-[Thi8,Met(O2)11]-substance P: a pilot trial
    D Cordier
    Division of Neurosurgery, University Hospitals, Basel, Switzerland
    Eur J Nucl Med Mol Imaging 37:1335-44. 2010
    ..Therefore, we evaluated locally injected (213)Bi-DOTA-substance P in patients with critically located gliomas as the primary therapeutic modality...
  25. doi request reprint Preoperative staging of non-small-cell lung cancer: comparison of whole-body diffusion-weighted magnetic resonance imaging and 18F-fluorodeoxyglucose-positron emission tomography/computed tomography
    Gregor Sommer
    Clinic of Radiology and Nuclear Medicine, University of Basel Hospital, Petersgraben 4, 4031, Basel, Switzerland
    Eur Radiol 22:2859-67. 2012
    ....
  26. ncbi request reprint Up-regulation of somatostatin receptor density on rat CA20948 tumors escaped from low dose [177Lu-DOTA0,Tyr3]octreotate therapy
    M Melis
    Department of Nuclear Medicine, Erasmus MC Rotterdam Rotterdam, The Netherlands
    Q J Nucl Med Mol Imaging 51:324-33. 2007
    ....